Decreasing delays in the diagnosis and treatment of rheumatoid arthritis in Brazil: a nationwide multicenter observational study

[21] Urata Y(2014)What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review Ann Rheum Dis 73 861-870

[22] Nakamura Y(2019)Window of opportunity in rheumatoid arthritis—definitions and supporting evidence: from old to new perspectives RMD Open 5 e000870-1923

[23] Furukawa K(2018)The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil Adv Rheumatol 58 9-1110

[24] Quinn MA(2012)Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials Ann Rheum Dis 71 1921-513

[25] Emery P(2011)The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study Rheumatology (Oxford) 50 1106-827

[26] Villeneuve E(1999)Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice Ann Rheum Dis 58 510-1288

[27] Nam JL(2019)Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries Semin Arthritis Rheum 48 821-60

[28] Bell MJ(2011)Time to treatment for new patients with rheumatoid arthritis in a major metropolitan city J Rheumatol 38 1282-992

[29] van Nies JA(2009)Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort Rheumatology (Oxford) 48 57-862

[30] Brouwer E(2012)Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study Ann Rheum Dis 71 989-undefined

[21] Urata Y(2014)What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review Ann Rheum Dis 73 861-870

[22] Nakamura Y(2019)Window of opportunity in rheumatoid arthritis—definitions and supporting evidence: from old to new perspectives RMD Open 5 e000870-1923

[23] Furukawa K(2018)The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil Adv Rheumatol 58 9-1110

[24] Quinn MA(2012)Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials Ann Rheum Dis 71 1921-513

[25] Emery P(2011)The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study Rheumatology (Oxford) 50 1106-827

[26] Villeneuve E(1999)Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice Ann Rheum Dis 58 510-1288

[27] Nam JL(2019)Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries Semin Arthritis Rheum 48 821-60

[28] Bell MJ(2011)Time to treatment for new patients with rheumatoid arthritis in a major metropolitan city J Rheumatol 38 1282-992

[29] van Nies JA(2009)Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort Rheumatology (Oxford) 48 57-862

[30] Brouwer E(2012)Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study Ann Rheum Dis 71 989-undefined